Public Health, Versorgungsforschung und HTA

Publication List: 2006 - 2017

Last modified: July 4, 2017
 

 

2017

300.

Hörster L, Schlenk RF, Stadler M, Gabriel M, Thol F, Schildmann J, Vollmann J, Rochau U, Sroczynski G, Wasem J, Ganser A, Port M, Neumann A. Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotype. Leuk Res. 2017; 62:84-90.

299.

Jahn B, Arvandi M, Rochau U, Fiegl H, Goebel G, Marth C, Siebert U. Development of a novel prognostic score for breast cancer patients using mRNA expression of CHAC. BMC Cancer 2017 [in press].

298.

Adarkwah CC, Jegan N, Kuerwitz S, Heinzel-Gutenbrunner M, Kuehne F, Siebert U, Popert U, Donner-Banzhoff N. Cardiovascular risk assessment in younger patients: Implications of different risk representation on risk perception and decisional conflict. Z Allg Med 2017 [in press].Adarkwah CC, Jegan N, Kuerwitz S, Heinzel-Gutenbrunner M, Kuehne F, Siebert U, Popert U, Donner-Banzhoff N. Cardiovascular risk assessment in younger patients: Implications of different risk representation on risk perception and decisional conflict. Zeitschrift für Allgemeinmedizin 2017 [in press].

297.

Jahn B, Rochau U, Kurzthaler C, Hubalek M, Miksad R, Sorczynski G,
Paulden M, Bundo M, Stenehjem D, Brixner D, Krahn M, Siebert U.
Personalized treatment of women with early breast cancer: a risk-group
specific cost-effectiveness analysis of adjuvant chemotherapy accounting
for companion prognostic tests OncotypeDX and Adjuvant!Online. BMC
Cancer 2017 [in press].

296.

Christensen KD, Uhlmann WR, Roberts JS, Linnenbringer E, Whitehouse PJ, Royal CDM, Obisesan TO, Cupples LA, Butson MB, Fasaye GA, Hiraki S, Chen CA, Siebert U, Cook-Deegan R, Green RC. A randomized controlled trial of disclosing Genetic risk information for Alzheimer's disease via telephone. Genetics in Medicine 2017 [in press].

295.

Mühlberger N, Boskovic K, Krahn MD, Bremner KE, Oberaigner W, Klocker H, Horninger W, Sroczynski G, Siebert U. Benefits and Harms of Prostate Cancer Screening - Predictions of the ONCOTYROL Prostate Cancer Outcome and Policy Model. BMC Public Health 2017 [in press].

294.

Geiger-Gritsch S, Buchberger W, Knapp R, Daniaux M, Tabar L, Marth, Hubalek M, Edlinger M, Siebert U, Oberaigner W. Reduction in advancedbreast cancer and changes in breast cancer therapy after introduction of a mammography screening program in Tyrol/Austria. The Breast 2017 [in press].

293.

Schiller-Frühwirth IC, Jahn B, Arvandi M, Siebert U. Cost-effectiveness models in breast cancer screening in the general population: A systematic review. Appl Health Econ Health Policy 2017;15(3): 333-351.

292.

Di Paolo A, Sarkozy F, Ryll B, Siebert U. Personalized medicine in Europe: not yet personal enough? BMC Health Services Research 2017 [in press].

291.

Bose-O'Reilly S, Bernaudat L, Siebert U, Roider G, Nowak D, Drasch G. Signs and symptoms of mercury exposed gold miners. International Journal of Occupational Medicine and Environmental Health 2017; 30(2):1-21.

290.

Loeb S, Curnyn C, Walter D, Fagerlin A, Siebert U, Mühlberger N, Braithwaite RS, Schwartz MD, Lepor H, Sedlander E. Health state utilities among contemporary prostate cancer patients on active surveillance. Transl Androl Urol 2017 [in press].

289.

Schulc E, Gothe R, Tufan I, Them C, Mueller G. Self-Reported Questionnaire of Functional Health (Q-FH2) of Home-Dwelling Elderly People Living in Austria – Based on the Patient Questionnaire of theStandardized Assessment of Elderly People in Primary Care (STEP). Journal of Nursing Measurement 2017 [in press].

288.

Semsroth S, Matteucci Gothe R, Raith YR, de Brabandere K, Hanspeter E,Kilo J, Kofler M, Müller L, Ruttman-Ulmer E, Grimm M. Comparison of twominimally invasive techniques and median sternotomy in aortic valvereplacement. The Annals of Thoracic Surgery 2017 [in press].

287.

Czarnecka-Kujawa K, Rochau U, Siebert U, Atenafu E, Darling G, Waddell TK, De Perrot M, Pierre A, Cypel M, Keshavjee S, Yasufuku K. Cost-Effectiveness of Mediastinal Lymph Node Staging in NSCLC. The Journal of Thoracic and Cardiovascular Surgery 2017 [in press].

286.

Schnell-Inderst P, Iglesias CP, Arvandi M, Ciani O, Matteucci Gothe R, Peters J, Blom AW, Taylor RS, Sculpher M, Siebert U. Synthesis of RCT and observational data: a bias-adjusted evidence synthesis of total hip replacement. Health Econ. 2017 Feb;26 Suppl 1:46-69. doi: 10.1002/hec.3474.

 

2016

285.

Arvandi M, Strasser B, Meisinger C, Volaklis K, Gothe RM, Siebert U, Ladwig KH, Grill E, Horsch A, Laxy M, Peters A, Thorand B. Gender differences in the association between grip strength and mortality in older adults: results from the KORA-age study. BMC Geriatrics 2016;16(1):201 [epub]

284.

Adarkwah CC, Jegan N, Heinzel-Gutenbrunner M, Kühne F, Siebert U, Popert U, Donner-Banzhoff N, Kürwitz S. Time-to-event versus ten-year-absolute-risk in cardiovascular risk prevention - does it make a difference? Results from the Optimizing-Risk-Communication (OptRisk) randomized-controlled trial. BMC Med Inform Decis Mak. 2016;16(1):152.

283.

Hunger T, Schnell-Inderst P, Sahakyan N, Siebert U. Using expert opinionin health technology assessment: a guideline review. InternationalJournal of Technology Assessment in Health Care 2016;1-9, 2016 Aug 9.

282.

Dams J, Balzer-Geldsetzer M, Siebert U, Deuschl G, Schuepbach WM, Krack P, Timmermann , Schnitzler A, Reese JP, Dodel R, EARLYSTIM-investigators. Cost-effectiveness of neurostimulation in Parkinson's disease with early motor complications. Movement Disorders 2016;31(8):1183-91.

281.

Bose-O'Reilly S, Schierl R, Nowak D, Siebert U, Jossep FW, Fradico TO, Yuyun I Ir. A preliminary study on health effects in villagers exposed to mercury in a small-scale artisanal gold mining area in Indonesia. Environmental Research 2016; 149:274-81.

280.

Luzak A; Schnell-Inderst P; Buhn S; Mayer-Zitarosa A; Siebert U. Clinical effectiveness of cancer screening biomarker tests offered as self-pay health service: a systematic review. European Journal of Public Health 2016; 26(3):498-505.

279.

Ha E, Basu N, Bose-O'Reilly S, Dórea JG, McSorley E, Sakamoto M, Chan HM. Current progress on understanding the impact of mercury on human health. Environ Res. 2016; [Epub ahead of print].

278.

Jahn B, Rochau U, Kurzthaler C, Paulden M, Kluibenschädl M, Arvandi M, Kühne F, Goehler A, Krahn M, Siebert U. Lessons learned from a cross-model validation between a discrete event simulation model and a cohort state-transition model for personalized breast cancer treatment. Medical Decision Making 2016;36(3):375-90.

277.

Gschmeidler B, Flatscher-Thöni M, Knitel-Grabher E. Genetics in the medical and psychosocial practice: on the role of value hierarchies in counselling, Journal of Public Health 2016 [epub 16 March 2016].

276.

Leoni-Scheiber C, Matteucci Gothe R, Müller-Staub M. Die Einstellung deutschsprachiger Pflegefachpersonen gegenüber dem «Advanced Nursing Process» vor und nach einer Bildungsintervention – Quasi-experimentelle Interventionsstudie. Pflege 2016; 29(1):33-42.

275.

Ultsch B, Damm O, Beutels P, Bilcke J, Bruggenjurgen B, Gerber-Grote A, Greiner W, Hanquet G, Hutubessy R, Jit M, Knol M, von Kries R, Kuhlmann A, Levy-Bruhl D, Perleth M, Postma M, Salo H, Siebert U, Wasem J, Wichmann O. Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. Pharmacoeconomics 2016;34(3):227-44.

274.

Willenbacher E, Weger R, Rochau U, Siebert U, Willenbacher W, on behalf of the Austrian Myeloma Registry (AMR). Real-world use of 3rd line therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) analysis of the therapeutic landscape and clinical outcomes prior to the use of next generation myeloma therapeutics. PLoS One 2016; DOI: 10.1371.

273.

Leichtfried V, Basic D, Burtscher M, Gothe RM, Siebert U, Schobersberger W. Diagnosis and prediction of the occurrence of acute mountain sickness measuring oxygen saturation--independent of absolute altitude?. Sleep & Breathing 2016;20(1):435-42.

272.

Völzke H, Caron P, Dahl L, de Castro JJ, Erlund I, Gaberšček S, Gunnarsdottir I, Hubalewska-Dydejczyk A, Ittermann T, Ivanova L, Karanfilski B, Khattak RM, Kusić Z, Laurberg P, Lazarus JH, Markou KB, Moreno-Reyes R, Nagy EV, Peeters RP, Pīrāgs V, Podoba J, Rayman MP, Rochau U, Siebert U, Smyth PP, Thuesen BH, Troen A, Vila L, Vitti P, Zamrazil V, Zimmermann MB, John Lazarus, for the Iodine Global Network (IGN) West Central Europe group. Ensuring effective prevention of iodine-deficiency disorders. Thyroid 2016;26(2):189-96.

271.

Stenehjem D, Bellows BK, Yager KM, Jones J, Kaldate R, Siebert U, Brixner D. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer. The Oncologist 2016;21(2):196-204. 

270.

Latimer NR, Henshall C, Siebert U, Bell H. Treatment Switching: statistical and decision-making challenges and approaches. International Journal of Technology Assessment in Health Care 2016;32(3):160–6.

 

2015

269.

Mühlberger N, Kurzthaler C, Iskandar R, Krahn MD, Bremner KE, Oberaigner W, Klocker H, Horninger W, Conrads-Frank A, Sroczynski G, Siebert U. The ONCOTYROL Prostate Cancer Outcome and Policy Model – Effect of Prevalence Assumptions on the Benefit-Harm Balance of Screening. Medical Decision Making 2015 [Epub ahead of print]. 

268.

Jahn B, Rochau U, Kurzthaler C, Hubalek M, Miksad R, Sroczynski G, Paulden M., Kluibenschädl M., Krahn M., Siebert U. Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria. SpringerPlus 2015;4:752.

267.

Schwarzer R, Rochau U, Saverno K, Jahn B, Bornschein B, Muehlberger N, Flatscher-Thoeni M, Schnell-Inderst P, Sroczynski G, Lackner M, Schall I, Hebborn A, Pugner K, Fehervary A, Brixner D, Siebert U. Systematic overview of cost-effectiveness thresholds in ten countries across four continents. Journal of Comparative Effectiveness Research 2015;4(5):485-504.
Fulltext (Open Access) 

266.

Leichtfried V, Basic D, Martin Burtscher M, Matteucci Gothe R, Siebert U, Schobersberger W.: Diagnosis and prediction of the occurrence of acute mountain sickness measuring oxygen saturation – independent of absolute altitude? Sleep and Breathing, March 2016, Volume 20, Issue 1, pp 435-442.

265.

Nachtnebel A, Mayer J, Erdös J, Lampe K, Kleijnen S, Schnell-Inderst P, Wild C. HTA goes Europe: Europäische Zusammenarbeit in gemeinsamen Nutzenbewertungen und methodischen Fragen wird real. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 2015;109(4–5):291–99.

264.

Schnell-Inderst P, Mayer J, Lauterberg J, Hunger T, Arvandi M, Conrads-Frank A, Nachtnebel A, Wild C, Siebert U. Health technology assessment of medical devices: What is different? An overview of three European projects. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 2015;109(4-5):309-18.

263.

Siebert U, Jahn B, Rochau U, Schnell-Inderst P, Kisser A, Hunger T, Sroczynski G, Mühlberger N, Willenbacher W, Schnaiter S, Endel G, Huber LA, Gastl G, on behalf of the  Oncotyrol HTA & Outcomes Research Working Group. Oncotyrol - Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 2015;109(4-5):330-40.

262.

Gothe H, Schall I, Saverno K, Mitrovic M, Luzak A, Brixner D, Siebert U. The Impact of Generic Substitution on Health and Economic Outcomes: A Systematic Review. Appl Health Econ Health Policy 2015;13 (Suppl 1):S21-33.

261.

Rochau U, Sroczynski G, Wolf D, Schmidt S, Jahn B, Kluibenschaedl M, Conrads-Frank A, Stenehjem D, Brixner D, Radich J, Gastl G, Siebert U. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Leuk Lymphoma 2015; 56(8):2315-25.

260. Christensen KD, Dukhovny D, Siebert U, Green RC. Assessing the Costs and Cost-Effectiveness of Genomic Sequencing. [Review]. Journal of Personalized Medicine 2015;5(4):470-86.
 
259. Rochau U, Kluibenschaedl M, Stenehjem D, Kuan-Ling K, Radich J, Oderda G, Brixner D, Siebert U. Effectiveness and cost-effectiveness of sequential treatment of patients with chronic myeloid leukemia in the United States - a decision analysis. Leukemia Research and Treatment 2015 [Epub 2015 Dec 10].
 

258.

Semsroth S, Matteucci Gothe R, Heinz A, Dal Capello T, Kilo J, Müller L, Grimm M, Ruttman-Ulmer E. Comparison of anterolateral minithoracotomy versus partial upper hemisternotomy in aortic valve replacement. Annals of Thoracic Surgery, 2015; 100(3):868-73.

257.

Tülü S, Mulino M, Pinggera D, Luger M, Würtinger P, Grams A, Bodner T, Beer R, Helbok R, Matteucci Gothe R, Unterhofer C, Gizewski E, Schmutzhard E, Thomé C, Ortler M. Remote ischemic preconditioning in the prevention of ischemic brain damage during intracranial aneurysm treatment (RIPAT): study protocol for a randomized controlled trial. Trials 2015;16:594 [ePub DOI 10.1186/s13063-015-1102-6].

256.

Vogler S, Lepuschütz L, Schneider P, Stühlinger V. Study on enhanced cross-country coordination in the area of pharmaceutical product pricing, Luxembourg: Publications Office of the European Union, 2015, ISBN 978-92-79-53462-1, doi: 10.2875/631265.

255.

Flatscher-Thöni M, Leiter-Scheiring A, Schusterschitz C. The supply side of volunteering in Austrian hospice services: Determinants of sustainable voluntary engagement. Journal of Public Health 2015;23(4):189-99.

254.

Flatscher-Thöni M, Voithofer C. Should Reproductive Medicine be harmonized within Europe? European Journal of Health Law 2015;22(1): 61-74.

253.

Flatscher-Thöni M, Voithofer C, Werner-Felmayer G. Fortpflanzungesmedizingesetz 2015: Lang ersehnte Liberalisierung ohne unerwünschte Nebenwirkungen? juridikum - zeitschrift für kritik - recht – gesellschaft 2015;1:26.  

252.

Voithofer C, Flatscher-Thöni M. Öffnung der Fortpflanzungsmedizin für Frauenpaare, Interdisziplinäre Zeitschrift für Familienrecht 2015;1:9. 

251.

Raich M, Adler C, Stühlinger V, Lorenzoni N, Duschek S. Impact of Major Incidents on Health System Performance, Security and Health Protection, in Brebbia C.A. (Ed), Sustainable Development, Vol. 2, 1111 – 1121, WIT Press (Southampton, Boston), 2015, ISSN: 1746-4498 (print), ISSN: 1743-3509 (on-line).

250.

Oostvogels AJ, DE Wit GA, Jahn B, Cassini A, Colzani E, DE Waure C, Kretzschmar ME, Siebert U, Mühlberger N, Mangen MJ. Use of DALYs in economic analyses on interventions for infectious diseases: a systematic review. Epidemiol Infect. 2015;143(9):1791-802.

249.

Rochau U, Jahn B, Qerimi V, Burger EA, Kurzthaler C, Kluibenschaedl M, Willenbacher E, Gastl G, Willenbacher W, Siebert U. Decision-analytic modeling studies: An overview for clinicians using multiple myeloma as an example. Critical Reviews in Oncology/Hematology 2015;94(2):164-178.

248.

Neumann A, Mostardt S, Biermann J, Gelbrich G, Goehler A, Geisler BP, Siebert U, Störk S, Ertl G, Angerrmann CE, Wasem J. Cost-effectiveness and cost-utility of a structured collaborative disease management in the Interdisciplinary Network for Heart Failure (INH) study. Clin Res Cardiol. 2015;104(4):304-9.

247.

Stollenwerk B, Lhachimi SK, Briggs A, Fenwick E, Caro JJ, Siebert U, Danner M, Gerber-Grote A. Communicating the parameter uncertainty in the IQWiG efficiency frontier to decision-makers. Health Econ 2015;24(4):481-90.

246.

Swart E, Gothe H, Geyer S, Jaunzeme J, Maier B, Grobe TG, Ihle P. [Good Practice of Secondary Data Analysis (GPS): guidelines and recommendations]. Gesundheitswesen. 2015 Feb;77(2):120-6.

245.

Diaby V, Goeree R, Hoch J, Siebert U. Multi-criteria decision analysis for health technology assessment in Canada: insights from an expert panel discussion. Expert Rev Pharmacoecon Outcomes Res. 2015;15(1):13-9.

244.

Rogowski W, Payne K, Schnell-Inderst P, Manca A, Rochau U, Jahn B, Alagoz O, Leidl R, Siebert U. Concepts of 'personalization' in personalized medicine: implications for economic evaluation. Pharmacoeconomics 2015;33(1):49-59.

243.

Geiger-Gritsch S, Oberaigner W, Mühlberger N, Siebert U, Ladurner M, Klocker H, Horninger W. Patient-Reported Urinary Incontinence and Erectile Dysfunction Following Radical Prostatectomy: Results from the European Prostate Centre Innsbruck. Urologia Internationalis. 2015; 94(4):419-27.

 

 2014

242.

Rochau U, Schwarzer R, Jahn B, Sroczynski G, Kluibenschaedl M, Wolf D, Radich J, Brixner D, Gastl G, Siebert U. Systematic assessment of decision-analytic models for chronic myeloid leukemia. Appl Health Econ Health Policy 2014;12(2):103-15.

241.

Obach D, Deuffic-Burban S, Esmat G, Anwar WA, Dewedar S, Canva V, Cousien A, Doss W, Mostafa A, Pol S, Buti M, Siebert U, Fontanet A, Mohamed MK, Yazdanpanah Y. Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt. Clin Infect Dis 2014;58(8):1064-71.

240.

Blatt, CR, Storb, B, Mühlberger, N, Farias, MR, Siebert, U. Chronic Hepatitis C treatment for genotype 2 or 3 in Brazil: cost effectiveness analysis of peginterferon plus ribavirin as first choice treatment. Brazilian Journal of Pharmaceutical Sciences 2014; 50(2):345-352.

239.

Siebert U. Arvandi M. M Gothe R. Bornschein B. Eccleston D. L Walters D. Rankin J. De Bruyne B. F Fearon W. H Pijls N. Harper R. Improving the Quality of Percutaneous Revascularisation in Patients with Multivessel Disease in Australia: Cost-Effectiveness, Public Health Implications, and Budget Impact of FFR-Guided PCI. Heart, Lung & Circulation 2014;23(6):527-33.

238.

Zeller T, Hughes M, Tuovinen T, Schillert A, Conrads-Frank A, den Ruijter H, Schnabel RB, Kee F, Salomaa V, Siebert U, Thorand B, Ziegler A, Breek H, Pasterkamp G, Kuulasmaa K, Koenig W, Blankenberg S on behalf of the BiomarCaRE consortium. BiomarCaRE - rationale and design of the European BiomarCaRE Project including 300,000 participants from 13 European countries. Eur J Epidemiol. 2014;29(10):777-90.

237.

Rochau U, Sroczynski G, Wolf D, Schmidt S, Jahn B, Saverno K, Brixner D, Radich J, Siebert U. Medical Decision Analysis for the First-line Therapy of Chronic Myeloid Leukemia. Leukemia and Lymphoma 2014;55(8):1758-67.

236.

Steckling N, Bose-O'Reilly B, Pinheiro P, Plass D, Shoko D, Drasch G, Bernaudat L, Siebert U, Hornberg C. The burden of chronic mercury intoxication in artisanal small-scale gold mining in Zimbabwe: data availability and preliminary estimates. Environmental Health 2014;13:111.

235.

Leichtfried V, Matteucci Gothe R, Kantner-Rumplmair W, Mair-Raggautz M, Bartenbach C, Guggenbichler H, Gehmacher D, Jonas L, Aigner M, Winkler D, Schobersberger W. Short-term effects of bright light therapy in adults with chronic nonspecific back pain: a randomized controlled trial. Pain Med. 2014;15(12):2003-12.

234.

Schusterschitz C, Flatscher-Thöni M, Leiter-Scheiring A, Geser W. Building a committed volunteer workforce – Are it variables at the experience stage that count? Journal of Community and Applied Social Psychology 2014;24(5):422-38.

233.

Stühlinger V, Hackl M. Research Ethics Committees in the Field of Health-Related Human Research – A European Perspective and the Case of Austria, European Journal of Health Law 2014;21(4):, 387-400.

232.

Flatscher-Thöni M, Leiter-Scheiring A, Winner H. Schmerzensgeld in Österreich: Eine quantitative Betrachtung, Journal für Rechtspolitik 2014;22:85-9. 

231.

Voithofer C, Flatscher-Thöni M. VfGH vereinfacht Zugang zur Fortpflanzungsmedizin. Was passiert, wenn nichts passiert? Interdisziplinäre Zeitschrift für Familienrecht 2014;9(2):54-6.

230.

Flatscher-Thöni M, Voithofer C. Stellungnahme zum Entwurf eines Bundesgesetzes, mit dem das Fortpflanzungsmedizingesetz, das Allgemeine Bürgerliche Gesetzbuch und das Gentechnikgesetz geändert werden  Fortpflanzungsmedizinrechts-Änderungsgesetz 2015 – FMedRÄG 2015) - BMJ-Z3.509/0010-I 1/2014 (77/ME), November 2014. [Opinion paper].

229.

Stühlinger V, News from the European Association of Health Law, Bioethical Voices. Newsletter of the UNESCO Chair in Bioethics, September 2014:4. [Letter].

228.

Flatscher-Thöni M, Voithofer C. Austrian Constitutional Court: Recent decision on access to reproductive medicine, Bioethical Voices. Newsletter of the UNESCO Chair in Bioethics, December 2014:5. [Letter].

227.

Zechmeister-Koss I, Schnell-Inderst P, Zauner G. Appropriate Evidence Sources for Populating Decision Analytic Models within Health Technology Assessment (HTA): A Systematic Review of HTA Manuals and Health Economic Guidelines. Medical Decision Making 2014 [epub ahead of print].

226.

Rautenberg T, Siebert U, Arnold D, Bennouna J, Kubicka S, Walzer S, Ngoh C. Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer. J Med Econ 2014;17(2):99-110.

225.

Hunger T, Schnell-Inderst P, Hintringer K, Schwarzer R, Seifert-Klauss V, Gothe H, Wasem J, Siebert U. Health technology assessment of utilization, practice and ethical issues of self-pay services in the German ambulatory health care setting. Int J Public Health 2014;59(1):175-87.

224.

Saverno K, Gothe H, Schuessel K, Biskupiak J, Schulz M, Siebert U, Brixner D. Consideration of international generic distribution policies on patient outcomes in the United States and Germany. Pharmazie 2014;69(3):3.

223.

Rochau U, Schwarzer R, Jahn B, Sroczynski G, Kluibenschaedl M, Wolf D, Radich J, Brixner D, Gastl G, Siebert U. Systematic Assessment of Decision-Analytic Models for Chronic Myeloid Leukemia. Appl Health Econ Health Policy 2014:103-115.

222.

Rochau U, Sroczynski G, Wolf D, Schmidt S, Conrads-Frank A, Jahn B, Saverno K, Brixner D, Radich J, Gastl G, Siebert U. Medical decision analysis for first-line therapy of chronic myeloid leukemia. Leuk Lymphoma 2014;55(8):1758-67.

221.

Siebert U, Rochau U, Claxton K. When is enough evidence enough? – Using systematic decision analysis and value-of-information analysis to determine the need for further evidence. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 2013;107(9–10):575-584.

220.

Siebert U, Arvandi M, R MG, Bornschein B, Eccleston D, D LW, Rankin J, De Bruyne B, W FF, N HP, Harper R. Improving the Quality of Percutaneous Revascularisation in Patients with Multivessel Disease in Australia: Cost-Effectiveness, Public Health Implications, and Budget Impact of FFR-Guided PCI. Heart Lung Circ 2014:527-533.

219.

Nolte JE, Neumann T, Manne JM, Lo J, Neumann A, Mostardt S, Abbara S, Hoffmann U, Brady TJ, Wasem J, Grinspoon SK, Gazelle GS, Goehler A. Cost-effectiveness analysis of coronary artery disease screening in HIV-infected men. Eur J Prev Cardiol 2014;21(8):972-9.

 

2013

218.

Dams J, Klotsche J, Bornschein B, Reese JP, Balzer-Geldsetzer M, Winter Y, Schrag A, Siderowf A, Oertel WH, Deuschl G, Siebert U, Dodel R. Mapping the EQ-5D index by UPDRS and PDQ-8 in patients with Parkinson's disease. Health and Quality of Life Outcomes 2013;11(1):35.

217.

Weinberger B, Schirmer M, Matteucci Gothe R, Siebert U, Fuchs D, Grubeck-Loebenstein B. Recall Responses to Tetanus and Diphtheria Vaccination Are Frequently Insufficient in Elderly Persons. PLoS ONE 2013;8(12):e82967.

216.

Saverno K, Gothe H, Schuessel K, Biskupiak J, Schulz M, Siebert U, Brixner D. Consideration of international generic distribution policies on patient outcomes in the United States and Germany [accepted]. Pharmazie 2013:1-3.

215.

Siebert U, Rochau U, Claxton K. When is enough evidence enough? – Using systematic decision analysis and value-of-information analysis to determine the need for further evidence. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 2013;107(9–10):575-584.

214.

Haider T, Gunga HC, Matteucci‐Gothe R, Sottara E, Griesmacher A, Belavý DL, Felsenberg D, Werner A, Schobersberger W. Effects of long‐term head‐down‐tilt bed rest and different training regimes on the coagulation system of healthy men. Physiological Reports 2013;1(6).

213.

Institute for Quality and Efficiency in Health Care (IQWIG). Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments. Executive Summary. IQWiG Reports – Commission No. G09-01, IQWiG-Report – Nr. 190. Cologne, Germany: Institute for Quality and Efficiency in Health Care, 2013;1-626.

212.

Gschmeidler B, Flatscher-Thöni M. Ethical and Professional Challenges of Genetic Counseling - the Case of Austria. Journal of Genetic Counseling, 2013:22(6): 741-52.

211.

Flatscher-Thöni M, Leiter A, Winner H. Pricing Damages for Pain and Suffering in Court: The Impact of the Valuation Method. Journal of Empirical Legal Studies 2013;10(1):104–19.

210.

Stühlinger V, Schwamberger H. Forschung am Menschen im nichtärztlichen Bereich – Vorlagepflichten und Prüfmöglichkeiten durch Ethikkommissionen, Recht der Medizin (RdM) 2013; Issue 06, 146:283-9.

209.

Sroczynski G, Siebert U. Viral hepatitis: Cost-effectiveness of direct-acting antivirals for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013;10(10):572-574.

208.

Tanios N, Wagner M, Tony M, Baltussen R, van Til J, Rindress D, Kind P, Goetghebeur MM, and the International Task Force on Decision Criteria. Which criteria are considered in healthcare decisions? Insights from an international survey of policy and clinical decision makers. International Journal of Technology Assessment in Health Care 2013;29(4):456-65.

207.

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 2013;16(2):231-250.

206.

Sulz MC, Siebert U, Arvandi M, Gothe RM, Wurm J, von Kanel R, Vavricka SR, Meyenberger C, Sagmeister M. Predictors for hospitalization and outpatient visits in patients with inflammatory bowel disease: results from the Swiss Inflammatory Bowel Disease Cohort Study. Eur J Gastroenterol Hepatol 2013 25(7):790-797.

205.

Siebert U, Wurm J, Matteucci-Gothe R, Arvandi M, Vavricka S, von Kaenel R, Begre S, Sulz M, Meyenberger C, Sagmeister M, Group SICS. Predictors of Temporary and Permanent Work Disability in Patients with Inflammatory Bowel Disease Results of the Swiss Inflammatory Bowel Disease Cohort Study. Inflammatory Bowel Diseases 2013;19(4):847-855.

204.

Dams J, Klotsche J, Bornschein B, Reese JP, Balzer-Geldsetzer M, Winter Y, Schrag A, Siderowf A, Oertel WH, Deuschl G, Siebert U, Dodel R. Mapping the EQ-5D index by UPDRS and PDQ-8 in patients with Parkinson's disease. Health and Quality of Life Outcomes 2013;11(1):35.

203.

Strasser B, Siebert U, Schobersberger W. Effects of resistance training on respiratory function in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Sleep Breath 2013;17(1):217-26.

202.

Dams J, Siebert U, Bornschein B, Volksmann J, Deuschl G, Oertel W, Dodel R, Reese JP. Cost-Effectiveness of Deep Brain Stimulation in Patients with Parkinson’s Disease. Mov Disord 2013 28(6):763-71.

201.

Stollenwerk B, Gandjour A, Luengen M, Siebert U. Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation. European Journal of Health Economics 2013 14(6):1035-48.

 

2012

200.

Froeschl B, Bornschein B, Brunner-Ziegler S, Conrads-Frank A, Eisenmann A, Gartlehner G, Grillich L, Kaminski A, Muehlberger N, Pertl D, Schnell-Inderst P, Sroczynski G, Siebert U, Thaler K, Wild C, Wurm J, Zechmeister I, Zsifkovits J, Horvath K, Pueringer U, Grouven U, Kurth T, Luehmann D, Swart E, Neumann A, Landauer R. Methodenhandbuch für Health Technology Assessment Version 1.2012. Eine Kooperation von Donau-Universität Krems (DUK), EBM Review Center Graz, Gesundheit Österreich GmbH (GÖG), Ludwig Boltzmann Institut für HTA (LBI-HTA) und Privater Universität für Gesundheitswissenschaften, Medizinische Informatik und Technik (UMIT). Wien, Österreich: Im Auftrag des Bundesministeriums für Gesundheit, 2012;1-425.

Online abrufbar: http://www.goeg.at/

199.

Dimai HP, Redlich K, Peretz M, Borgstrom F, Siebert U, Mahlich J. Economic burden of osteoporotic fractures in Austria. Health Econ Rev 2012;2(1):12.

198.

Siebert U. [Transparent Decisions in Public Health Using Systematic Decision Analysis]. [German]. In: Schwartz FW, Badura B, Busse R, Leidl R, Raspe H, Siegrist J, Walter U (eds.): [The Public Health Book. Health and Health Care]. 3rd ed. Urban & Fischer: Munich, 2012.

197.

Deuffic-Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Muehlberger N, Siebert U, Moreno C, Hatzakis A, Rosenberg W, Zeuzem S, Mathurin P. Predicted Effects of Treatment for HCV Infection Vary Among European Countries. Gastroenterology 2012;143:974–85. 

196.

Caro JJ, Briggs AH, Siebert U, Kuntz KM, on Behalf of the ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling Good Research Practices - Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force -1. Value in Health 2012; 15:796-803.

195.

Caro JJ, Briggs AH, Siebert U, Kuntz KM, on Behalf of the ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling Good Research Practices - Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force -1. Medical Decision Making 2012; 32(5): 667-677.

Download Article

194.

Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, Kuntz KM. State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force -3. Value in Health 2012; 15: 812-820.

193.

Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, Kuntz KM. State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force -3. Medical Decision Making 2012; 32(5):690-700.

Download Article

192.

Verhoef TI, Redekop WK, van Schie RM, Bayat S, Daly AK, Geitona M, Haschke Becher E, Hughes DA, Kamali F, Levin LA, Manolopoulos VG, Pirmohamed M, Siebert U, Stingl JC, Wadelius M, de Boer A, Maitland-van der Zee AH. Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. Pharmacogenomics 2012;13(12):1405-17.

191.

Saverno, K., Stenehjem, D., et al. (2012). Application of Decision-Analytic Models in Personalized Medicine for CML Treatment Decisions Made by Payers, Providers, and Patients. Journal of Managed Care Pharmacy 18(6): 457-63.

190.

Blatt C, Bernardo N, Rosa JA, Bagatini F, Alexandre R, Balbinotto Neto G, Siebert U, Rocha Farias M. An Estimate of the Cost of Hepatitis C Treatment for the Brazilian Health System. Value in Health Regional Issues 2012;1(2):129-135.

189.

Steckling N, Boese-O'Reilly S, Pinheiro P, Plass D, Shoko D, Siebert U, Hornberg C. The burden of chronic mercury intoxication attributable to mercury use in artisanal small-scale gold mining in Zimbabwe. The Lancet 2012 [accepted].

188.

Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, Kuntz KM. State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Value in Health 2012;15:812-20. 

187.

Drummond M, Neumann P, Jönsson B, Luce B, Schwartz JS, Siebert U, Sullivan SD. Can we reliably benchmark health technology assessment organizations? International Journal of Technology Assessment in Health Care 2012;28(2):159-65.

186.

Bouchaud O, Muehlberger N, Parola P, Calleri G, Matteelli A, Peyerl-Hoffmann G, Méchai F, Gautret P, Clerinx J, Kremsner PG, Jelinek T, Kaiser A, Beltrame A, Schmid M, Kern P, Probst M, Bartoloni A, Weinke T, Grobusch MP. Therapy of uncomplicated falciparum malaria in Europe: MALTHER - a prospective observational multicentre study. Malaria Journal 2012;11:212.

185.

Faulkner E, Annemans L, Garrison L, Helfand M, Holtdorf AP, Hornberger J, Hughes D, Li T, Malone D, Payne K, Siebert U, Towse A, Veenstra D, Watkins J. for Personalized Medicine Development and Reimbursement Working Group. Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group. Value in Health 2012;15(8):1162-71.

184.

Kretzschmar M, Mangen MJ, Pinheiro P, Jahn B, Fevre EM, Longhi S, Lai T, Havelaar AH, Stein C, Cassini A, Kramarz P. New methodology for estimating the burden of infectious diseases in Europe. PLoS Med 2012;9(4):e1001205.

183.

Luce BR, Drummond MF, Dubois RW, Neumann PJ, Joensson B, Siebert U, Schwartz JS. Principles for planning and conducting comparative effectiveness research. Journal of Comparative Effectiveness Research 2012;1(5):431-40.

182.

Caro JJ, Briggs AH, Siebert U, Kuntz KM, Force obotI-SMGRPT. Modeling Good Research Practices - Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force -1. Medical Decision Making 2012;32(5):667-77.

181.

Dimai HP, Redlich K, Schneider H, Siebert U, Vierstein H, Mahlich J. [Direct and Indirect Costs of Fractures due to Osteoporosis in Austria]. Gesundheitswesen 2012;74(10):e90-e98.

180.

Siebert U, Rochau U. Personalisierte Krebstherapie. PharmacoEconomics 2012;10:87-104.

179.

Strasser B, Arvandi M, Siebert U. Resistance training, visceral obesity and inflammatory response: a review of the evidence. Obes Rev 2012;13(7):578-591.

178.

Oberaigner W, Siebert U, Horninger W, Klocker H, Bektic J, Schafer G, Frauscher F, Schennach H, Bartsch G. Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008. Int J Public Health 2012;57(1):57-62.

ABSTRACT

177.

Krobot KJ, Wagner A, Siebert U. Risk factor levels, risk factor combinations, and residual coronary risk: population-based estimates for secondary prevention patients using statins. Eur J Cardiovasc Prev Rehabil 2012;19(1):109-17.

ABSTRACT

176.

Oberaigner W, Minicozzi P, Bielska-Lasota M, Allemani C, De Angelis R, Mangone L, Sant M, EUROCARE Working Group. Survival for Ovarian Cancer in Europe: The across-country variation did not shrink in the past decade. Acta Oncol 2012;51(4):441-53.

ABSTRACT

175.

Rantner LJ, Stuhlinger MC, Nowak CN, Spuller K, Etsadashvili K, Stuhlinger X, Berger T, Dichtl W, Gothe RM, Fischer G, Hintringer F. Localizing the accessory pathway in ventricular preexcitation patients using a score based algorithm. Methods Inf Med 2012;51(1):3-12.

ABSTRACT

 

2011

174.

Nuijten MJ, Aultman R, Carpeno Jde C, Vergnenegre A, Chouaid C, Walzer S, Siebert U. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer. Curr Med Res Opin 2011;27(11):2193-201.

173.

Zechmeister I, Ara R, Ward S, Stollenwerk B. Have statins met our expectations? A comparison of excepted health gains from statins with epidemiological trends in Austria. Journal of Public Health 2011;20(1):31-9.

172.

Geiger-Gritsch S, Muehlboeck H, Harrasser L, Oberaigner W. Cancer in the Elderly and Gender Aspects - Situation in Tyrol. Magazine of European Medical Oncology 2011;4(4):232-35.

171.

Siebert U, Jahn B, Muhlberger N, Fricke F-U, Schoeffski O. [Decision Analysis and Modelling] [German]. In: Schöffski O, Graf von der Schulenburg JM, eds. Economic Evaluations, 4th. ed. Berlin, Heidelberg, New York: Springer, 2011;275-324.

170.

Baeuml J, Bose-O’Reilly S, Gothe RM, Lettmeier B, Roider G, Drasch G, Siebert U. Human biomonitoring data from mercury exposed miners in six artisanal small-scale gold mining areas in Asia and Africa. Minerals 2011;1(1):122-43.

169.

Sels J, Tonino P, Siebert U, Fearon W, Van't Veer M, De Bruyne B, Pijls N. Fractional Flow Reserve in Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction: Experience From the FAME (Fractional flow reserve versus Angiography for Multivessel Evaluation) Study. J Am Coll Cardiol Intv 2011;4(11):1183-9.

ABSTRACT

168.

Afandiyev I, Alimonti A, Barbosa Jr F, Besbelli N, Bose-O'Reilly S, Conti M, Danbayev Z, Dargan P, Domingo J, Drasch G, Dumitru C, Flegal A-R, Gardner R, Gecim N, Goldman L, Graczyk H, Gvineria I, Horvat M, De Kom J, Lettmeier B, Makalinao I, McCarty K, Adler-Miserendino R, Najaran L, Nyland J, Pantea V, Sakamoto M, Sharshenova A, Silbergeld E, Stern A, Steckling N, Wells E, Yamamoto M. Children’s Exposure to Mercury Compounds. Geneva, Switzerland: WHO Document Production Services, 2010.

167.

Amitai Y, Bakir H, Besbelli N, Boese-O'Reilly S, Cebrian M, Dai Y, Dargan P, Easson E, Graber N, Khassouani C, Healy N, Kolacinsiki Z, Laborde A, Landrigan P, Lanphear B, Mathee A, Mathieu M, McWeeny W. Childhood lead Poisoning. Geneva, Switzerland: WHO Document Production Services, 2010.

166.

Schnell-Inderst P, Hunger T, Hintringer K, Schwarzer R, Seifert-Klauss V, Gothe H, Wasem J, Siebert U. [Individual health services. Series of the German Institute for Medical Documentation and Information commissioned by the Federal Ministry of Health] [German]. Health Technology Assessment. Vol. 113 (1. Auflage). Köln: DAHTA@DIMDI, 2011.

165.

Gothe H, Storz P, Daroszewska A, Häussler B. Innovationen in der Anti-Aging-Medizin - Eine Analyse des Angebots, der Versorgungssituation und zukünftiger Entwicklungen an drei ausgewählten Beispielen. In: Maio G, ed. Altwerden ohne alt zu sein? - Ethische Grenzen der Anti-Aging-Medizin. Freiburg: Verlag Karl Alber, 2011;71-93.

164.

Ammenwerth E, Schnell-Inderst P, Hörbst A. Patient Empowerment by Electronic Health Records: First Results of a Systematic Review on the Benefit of Patient Portals. e-health Across Borders without Boundaries. EFMI Special Topic Conference (STC), April 14-15. Laško, Slovenia, Studies in Health Technology and Informatics. Amsterdam: IOS Press 2011; 165:63-67.

163.

Dams J, Bornschein B, Reese JP, Conrads-Frank A, Oertel W, Siebert U, Dodel R. Modelling the cost effectiveness of treatments for Parkinson´s Disease - A methodological review. Pharmacoeconomics 2011;29(12):1025-49.

ABSTRACT

162.

Mangen M-J, Gibbons C, Kretzschmar M, de Wit A, Havelaar A, van Lier A, Bijerk P, Siebert U, Jahn B, Muhlberger N, Krämer A, Plaß D, Pinheiro P, Ricciardi W, Franco E, Longhi S, Murianni L, de Waure C, Lai T, Rüütel K. Current and future Burden of Communicable Diseases in the European Union and EEA/ EFTA countries (BCoDE) - Methodology protocol [Technical Report]. Stockholm, Sweden: European Centre for Disease Prevention Control (ECDC), 2011;1-43.

161.

Oberaigner W, Siebert U. Do women with cancer have better survival as compared to men after adjusting for staging distribution? Eur J Public Health 2011;21(3)291:387-391.

ABSTRACT

160.

Oberaigner W, Daniaux M, Geiger-Gritsch S, Knapp R, Siebert U, Buchberger W. Introduction of organised mammography screening in Tyrol: results following first year of complete rollout. BMC PH 2011;11(673).

ABSTRACT

159.

Baeuml J, Bose-O’Reilly S, Lettmeier B, Maydl A, Messerer K, Roider G, Drasch G, Siebert U. Applicability of two mobile analysers for mercury in urine in small-scale gold mining areas. International Journal Hygiene Environmental Health 2011;215(1):64-7.

ABSTRACT

158.

Goehler A, Geisler BP, Manne JM, Jahn B, Conrads-Frank A, Schnell-Inderst P, Gazelle GS, Siebert U. Decision-Analytic models to simulate health outcomes and costs in heart failure: a systematic review. Pharmacoeconomics 2011;29(9):753-69.

ABSTRACT

157.

Jahn R, Diehm C, Driller E, Hessel F, Ommen O, Pfaff H, Siebert U, Pittrow D, Wasem J, Neumann A. Effect of guideline-orientation on the outcomes of peripheral arterial disease in primary care. Current Medical Research and Opinion 2011;27(6)286:1183-1190.

ABSTRACT

156.

Sroczynski G, Schnell-Inderst P, Muhlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry KU, Kramer A, Siebert U. Cost-effectiveness of primary HPV screening for cervical cancer in Germany - a decision analysis. Eur J Cancer 2011;47(11):1633-46.

ABSTRACT

155.

Mickisch GH, Schwander B, Escudier B, Bellmunt J, Maroto J P, Porta C, Walzer S, Siebert, U. Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. ClinicoEconomics and Outcomes Research 2011;3:19-27.

154.

von Campenhausen S, Winter Y, Silva AR, Sampaio C, Ruzicka E, Barone P, Poewe W, Guekht A, Mateus C, Pfeiffer KP, Berger K, Skoupa J, Botzel K, Geiger-Gritsch S, Siebert U, Balzer-Geldsetzer M, Oertel WH, Dodel R, Reese JP. Costs of illness and care in Parkinson's Disease: An evaluation in six countries. Eur Neuropsychopharmacol 2011;21(2):180-91.

ABSTRACT

153.

Oberaigner W, Buchberger W, Frede T, Daniaux M, Knapp R, Marth C, Siebert U. Introduction of organised mammography screening in Tyrol: results of a one-year pilot phase. BMC Public Health 2011;11(91):1-28.

152.

Steckling N, Boese-O'Reilly S, Gradel C, Gutschmidt K, Shinee E, Altangerel E, Badrakh B, Bonduush I, Surenjav U, Ferstl P, Roider G, Sakamoto M, Sepai O, Drasch G, Lettmeier B, Morton J, Jones K, Siebert U, Hornberg C. Mercury exposure in female artisanal small-scale gold miners (ASGM) in Mongolia: An analysis of human biomonitoring (HBM) data from 2008. Sci Total Environ 2011;409(5):994-1000.

ABSTRACT

151.

Leitner H, Bose-O'Reilly S, Oberaigner W, Mark M, Brezinka C, Siebert U. Perinatale Mortalität nach Herkunftsland der Mutter in Tirol 200-2008 [Perinatal Mortality by Mother's Country of Origin in Tyrol 2000-2008]. Gesundheitswesen 2011;73(8-9):469-76.

 

2010

150.

Fearon WF, Bornschein B, Tonino PA, Gothe RM, Bruyne BD, Pijls NH, Siebert U. Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. Circulation 2010;122(24):2545-50.

ABSTRACT

149.

Caro JJ, Nord E, Siebert U, McGuire A, McGregor M, Henry D, de Pouvourville G, Atella V, Kolominsky-Rabas P. The efficiency frontier approach to economic evaluation of health-care interventions. Health Econ 2010;19(10):1117-27.

ABSTRACT

148.

Caro JJ, Nord E, Siebert U, McGuire A, McGregor M, Henry D, de Pouvourville G, Atella V, Kolominsky-Rabas P. IQWiG methods - a response to two critiques. Health Econ 2010;19(10):1137-8.

147.

Geiger-Gritsch S, Stollenwerk B, Miksad R, Guba B, Wild C, Siebert U. Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist 2010:15(11):1179-91.

ABSTRACT

146.

Siebert U, Schnell-Inderst P, Hintringer K. Health Technology Assessment. medicine & health 2011. GoingInternational Polak, G., 2010;229-31.

145.

Oberbichler S, Memelink M, Wozak F, Jahn B, Schabetsberger T, Hoerbst A, Siebert U. INSYDE - Integration of Health System Data and Exchange - A Status Report. OCG Books 2010;264:181-87.

144.

Neumann PJ, Drummond MF, Jonsson B, Luce BR, Schwartz JS, Siebert U, Sullivan SD. Evaluating HTA principles - Letters to the Editor. Int J Technol Assess Health Care 2010;26(4):429-30.

143.

Lettmeier B, Drasch K, Boese-O'Reilly S, Drasch G. Vorschlag für Human-Biomonitoring-(HBM)-Werte für Quecksilberdampf – Teil I: Erwachsene. Umweltmedizin in Forschung und Praxis 2010;15(4):221-228.

142.

Lettmeier B, Böse-O’Reilly S, Roider G, Drasch G. Proposal for a Revised Reference Concentration (RfC) for mercury vapour in adults. Science of the total Environment 2010;408:3530-35.

141.

Leichtfried V, Kantner-Rumplmair W, Bartenbach C, Guggenbichler H, Gothe R, Schobersberger W. Bright light therapy: Minimizing light induced side effects with an innovative light setup. International Journal of Psychiatry in Clinical Practice 2010;14(4):309-12.

140.

Bose-O'Reilly S, McCarty K, Steckling N, Lettmeier B. Mercury exposure and children’s health. Current Problems in Pediatric and Adolescent Health Care 2010;40(8):186-215.

ABSTRACT

139.

Nuijten M, Heigener D, Bischoff H, Chouaid C, Vergnenègre A, Carpeño J, Aultman R, Walzer S, Siebert U. Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer. Lung Cancer 2010;69(Supplement 1):4-10.

ABSTRACT

138.

Klein S, Thiede M, Scholz C, Höer A, Albrecht M, Häussler B u.M.v. Stier V, Bleß H, de Millas C (IGES) / Schmidt H, Jahn R, Staudt S, Farrenkopf N, Lux G, Weegen L, Thomas D, Wasem J (Universität Duisburg-Essen) / Sussex J, Shah K, Butler J (Australian Centre for Economic Research on Health, The Australian National University, Canberra, Australia) (OHE Consulting) / Mühlberger N, Gothe H, Schwarzer R, Schnell-Inderst P, Sroczynski G, Siebert U u.M.v. Mayer C, Schall I, Iglesias C (UMIT). Gutachten zur Verbesserung der Wirtschaftlichkeit von Impfstoffen in Deutschland. Abschlussbericht. Im Auftrag des Bundesministeriums für Gesundheit [Hrsg.], Berlin 2010.

137.

Luce BR, Drummond M, Jonsson B, Neumann PJ, Schwartz JS, Siebert U, Sullivan SD. EBM, HTA, and CER: clearing the confusion. Milbank Q 2010;88(2):256-76.

ABSTRACT

136.

von Lengerke T, Hagenmeyer EG, Gothe H, Schiffhorst G, Happich M, Häussler B. Excess health care costs of obesity in adults with diabetes mellitus: a claims data analysis. Exp Clin Endocrinol Diabetes 2010; 118(8):496-504.

ABSTRACT

135.

Hagenmeyer EG, Gothe H, Landgraf W, Kulik M, Schiffhorst G, Häussler B. Ressourcen-Inanspruchnahme und Kosten der Behandlung von Typ-2-Diabetikern unter Insulin-glargin- oder Insulindetemir-Therapie (LIVE-KK): Analyse von Krankenkassen-Routinedaten mittels Propensity Score Matching. Gesundheitsökonomie und Qualitätsmanagement 2010; 15:121–6.

134.

Schiffhorst G, Freytag A, Höer A, Happich M, Häussler B, Gothe H. Pain-specific diagnosis patterns in claims data - Identification by means of classification and regression trees (CART). Gesundheitswesen 2010; 72(6):347-55.

ABSTRACT

133.

Ostendorf L, Gothe H. Antikörpertherapie in der Onkologie. Innovationen im Spiegel eines Prognoseinstrumentes. In: Häussler B, Isenberg T, Klusen N, Penk A. (Hrsg.): Jahrbuch der medizinischen Innovationen, Band 6: Innovation und Gerechtigkeit. ISBN 978-3-7945-2683-3. S. 129-136. Schattauer, Stuttgart, Germany, 2010.

132.

Gothe H, Klein S, Storz P, Höer A, Haag C, Marx P, Häussler B. Erkenntnisse zur Arzneimitteltherapie im Zeitverlauf: Frühe Ergebnisse und späte Umsetzung? Retrospektiove Untersuchung für ausgewählte Arzneimittel-Wirkstoffgruppen. Schriftenreihe Forschung und Entwickung im Gesundheitswesen, Band 2, ISBN 978-3-8329-5252-5. Nomos Verlagsgesellschaft, Baden-Baden, Germany, 2010.

131.

Expertenrat des Bundesministeriums für Bildung und Forschung (Gothe H, Grundwald A, Hackler E, Meyer S, Mollenkopf H, Niederlag W, Rienhoff O, Steinhagen-Thiessen, Szymkowiak C): Loccumer Memorandum. Technische Assistenzsysteme für den demographischen Wandel – eine generationenübergreifende Innovationsstrategie. Empfehlungen des Expertenrates des BMBF. Bundesministerium für Bildung und Forschung, Berlin, Germany, 2010.

130.

Schmidt T, Mühlberger N, Chemelli-Steingruber IE, Strasak A, Kofler B, Chemelli A, Siebert U. Benefit, risks and cost-effectiveness of screening for abdominal aortic aneurysm. Rofo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 2010;182(7):573-80.

ABSTRACT

129.

Pijls NH, Fearon WF, Tonino PA, Siebert U, Ikeno F, Bornschein B, van't Veer M, Klauss V, Manoharan G, Engstrom T, Oldroyd KG, Ver Lee PN, MacCarthy PA, De Bruyne B. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol 2010;56(3):177-84.

ABSTRACT

128.

Verhoef TI, Redekop WK, Darba J, Geitona M, Hughes DA, Siebert U, de Boer A, Maitland-van der Zee AH, Barallon R, Briz M, Daly A, Haschke-Becher E, Kamali F, Kirchheiner J, Manolopoulos VG, Pirmohamed M, Rosendaal FR, van Schie RM, Wadelius M. A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. Pharmacogenomics 2010;11(7):989-1002.

ABSTRACT

127.

Strasser B, Siebert U, Schobersberger W. Resistance training in the treatment of the metabolic syndrome: a systematic review and meta-analysis of the effect of resistance training on metabolic clustering in patients with abnormal glucose metabolism. Sports Med 2010;40(5):397-415.

ABSTRACT

126.

Sroczynski G, Schnell-Inderst P, Mühlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry KU, Krämer A, Siebert U. [Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany]. Health Technology Assessment. Cologne: DIMDI, 2010;1-127.

125.

Basner M, Siebert U. Markov processes for the prediction of aircraft noise effects on sleep. Medical Decision Making 2010; 30(2):275-89.

ABSTRACT

124.

Jahn B, Theurl E, Siebert U, Pfeiffer KP. Tutorial in medical decision modeling incorporating waiting lines and queues using discrete event simulation. Value Health 2010;13(4):501-6.

ABSTRACT

123.

Grander W, Dunser M, Stollenwerk B, Siebert U, Dengg C, Koller B, Eller P, Tilg H. C-reactive protein levels and post-ICU mortality in nonsurgical intensive care patients. Chest 2010;138(4):856-62.

ABSTRACT

122.

Sroczynski G, Schnell-Inderst P, Mühlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry KU, Krämer A, Siebert U. [Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany]. GMS Health Technol Assess 2010;6(Doc05 ):1-13.

121.

Rotter T, Kinsman L, James E, Machotta A, Gothe H, Willis J, Snow P, Kugler J. Clinical pathways: effects on professional practice, patient outcomes, length of stay and hospital costs. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 2010.

ABSTRACT

120.

Ammenwerth E, Schnell-Inderst P, Siebert U. Vision and challenges of Evidence-Based Health Informatics: a case study of a CPOE meta-analysis. Int J Med Inform 2010;79(4):e83-8.

ABSTRACT

119.

Stollenwerk B, Stock S, Siebert U, Lauterbach KW, Holle R. Uncertainty assessment of input parameters for economic evaluation: Gauss's error propagation, an alternative to established methods. Med Decis Making 2010;30(3):304-13.

ABSTRACT

118.

Oberaigner W, Buchberger W, Frede T, Knapp R, Marth C, Siebert U. Breast cancer incidence and mortality in Tyrol/Austria after fifteen years of opportunistic mammography screening. BMC Public Health 2010;10(1):86.

ABSTRACT

117.

Konig A, Bleie O, Rieber J, Jung P, Schiele TM, Sohn HY, Leibig M, Siebert U, Klauss V. Intravascular ultrasound radiofrequency analysis of the lesion segment profile in ACS patients. Clin Res Cardiol 2010;99(2):83-91.

ABSTRACT

116.

Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Mühlberger N, Wright D, Zeuzem Z, Siebert U. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. J Viral Hep 2010;17(1):34-50.

ABSTRACT

115.

Bose-O'Reilly S, Drasch G, Beinhoff C, Rodrigues-Filho S, Roider G, Lettmeier B, Maydl A, Maydl S, Siebert U. Health assessment of artisanal gold miners in Indonesia. Sci Total Environ 2010;408(4):713-25.

ABSTRACT

114.

Bose-O'Reilly S, Drasch G, Beinhoff C, Tesha A, Drasch K, Roider G, Taylor H, Appleton D, Siebert U. Health assessment of artisanal gold miners in Tanzania. Sci Total Environ 2010;408(4):796-805.

ABSTRACT

113.

International Working Group for HTA Advancement, Neumann PJ, Drummond MF, Jönsson B, Luce BR, Schwartz JS, Siebert U, Sullivan SD. Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations? International Journal of Technology Assessment in Health Care 2010; 26(1):71-78.

Full Text

112.

Schnell-Inderst P, Schwarzer R, Gohler A, Grandi N, Grabein K, Stollenwerk B, Manne J, Klauss V, Siebert U, Wasem J. Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: a health technology assessment report. Int J Technol Assess Health Care 2010;26(1):30-9.

ABSTRACT

111.

Geisler BP, Widerberg KF, Berghofer A, Willich SN. Leadership in Health Care: Developing a Post-merger Strategy for Europe’s Largest University Hospital J Health Organ Manag 2010 4(3):258-76.

ABSTRACT

110.

Kollensperger M, Geser F, Ndayisaba JP, Boesch S, Seppi K, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M, Klockgether T, Yekhlef F, Tison F, Daniels C, Deuschl G, Coelho M, Sampaio C, Bozi M, Quinn N, Schrag A, Mathias CJ, Fowler C, Nilsson CF, Widner H, Schimke N, Oertel W, Del Sorbo F, Albanese A, Pellecchia MT, Barone P, Djaldetti R, Colosimo C, Meco G, Gonzalez-Mandly A, Berciano J, Gurevich T, Giladi N, Galitzky M, Rascol O, Kamm C, Gasser T, Siebert U, Poewe W, Wenning GK. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 2010;25(15):2604-12.

ABSTRACT

 

2009

109.

Tonino PA, De Bruyne B, Pijls NHJ, Siebert U, Ikeno F, van't Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF, for the FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. New England Journal of Medicine 2009;360(3):213-24.

ABSTRACT

108.

Rotter T, Kinsman L, James E, Machotta A, Gothe H, Kugler J. The experience of conducting a Cochrane systematic review of the impact of clinical pathways on professional practice, patient outcomes, length of stay and hospital costs. International Journal of Care Pathways 2009; 13:62–6.

107.

Gothe H. Arbeits- und Berufszufriedenheit von Ärzten – eine Übersicht der internationalen Literatur. In: Schwartz FW, Angerer P (Hrsg.): Arbeitsbedingungen und Befinden von Ärztinnen und Ärzten – Befunde und Interventionen. Report Versorgungsforschung Band 2. ISBN 978-3-7691-3438-4. S. 7-14. Bundesärztekammer, Berlin, 2009.

106.

Gothe H, Storz P, Daroszewska A, Freytag A, Häussler B. Telemonitoring herzinsuffizienter Patienten: Gesundheitliche und ökonomische Effekte der künftigen Nutzung von AAL-Technologien. In: Schreyer G, Hayn D, Ammenwerth E (Hrsg.): eHealth 2009 – Health Informatics meets eHealth. ISBN 978-3-85403-250-2. S. 11-16. Österreichische Computer Gesellschaft, Wien, Austria, 2009.

105.

Freytag A, Schiffhorst G, Thoma R, Strick K, Gries C, Becker A, Treede RD, Müller-Schwefe G, Casser HR, Luley C, Höer A, Ujeyl M, Gothe H, Kugler J, Glaeske G, Häussler B. Identifikation und Gruppierung von Schmerzpatienten anhand von Routinedaten einer Krankenkasse. Schmerz 2009; 24:12-22.

ABSTRACT

104.

Trikalinos TA, Siebert U, Lau J. Decision-analytic modelling to evaluate benefits and harms of medical tests. Medical Tests-White Paper Series. Rockville: Agency for Healthcare Research and Quality (AHRQ), 2009;1-15.

Full Text

103.

Wild C, Simpson S, Douw K, Geiger-Gritsch S, Mathis S, Langer T. Information service on new and emerging health technologies: Identification and prioritization processes for a European Union-wide newsletter. International Journal of Technology Assessment in Health Care 2009;25(SupplementS2):48-55.

ABSTRACT

102.

von Campenhausen S, Winter Y, Gasser J, Seppi K, Reese JP, Pfeiffer KP, Geiger-Gritsch S, Botzel K, Siebert U, Oertel WH, Dodel R, Poewe W. [Cost of illness and health service patterns in Morbus Parkinson in Austria]. Wien Klin Wochenschr 2009;121(17-18):574-82.

ABSTRACT

101.

Geiger-Gritsch S, Piso B, Guba B, Felder-Puig R. Stentgraftimplantation bei Erkrankungen der Aorta ascendens. Der Chirurg 2009;80(7):634-640.

100.

Geisler BP. Health state survey-derived utilities in cost-utility analysis--a call to action. Value Health 2010;13(2):159.

ABSTRACT

99.

Schwarzer R, Schnell-Inderst P, Grabein K, Gohler A, Stollenwerk B, Grandi N, Klauss V, Wasem J, Siebert U. [Prognostic value and clinical effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events]. Z Evid Fortbild Qual Gesundhwes 2009;103(6):319-29.

ABSTRACT

98.

Jahn B, Pfeiffer KP, Theurl E, Tarride JE, Goeree R. Capacity constraints and cost-effectiveness: a discrete event simulation for drug-eluting stents. Med Decis Making 2010;30(1):16-28.

ABSTRACT

97.

Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report - Part III. Value in Health 2009; 12(8):1062-1073.

ABSTRACT

96.

Oberaigner W, Siebert U. Are survival rates for Tyrol published in the Eurocare studies biased? Acta Oncol 2009;48(7):984 - 991.

ABSTRACT

95.

Konig A, Bleie O, Rieber J, Jung P, Schiele TM, Sohn HY, Leibig M, Siebert U, Klauss V. Intravascular ultrasound radiofrequency analysis of the lesion segment profile in ACS patients. Clin Res Cardiol 2010;99(2):83-91.

ABSTRACT

94.

Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML. Good research practices for comparative effectiveness research: Approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report-Part II. Value Health 2009;12(8):1053-1061.

ABSTRACT

93.

Trikalinos TA, Siebert U, Lau J. Decision-analytic modeling to evaluate benefits and harms of medical tests: Uses and limitations. Med Decis Making 2009;29(5):E22-9.

ABSTRACT

92.

Mehrhof F, Loffler M, Gelbrich G, Ozcelik C, Posch M, Hense HW, Keil U, Scheffold T, Schunkert H, Angermann C, Ertl G, Jahns R, Pieske B, Wachter R, Edelmann F, Wollert KC, Maisch B, Pankuweit S, Erbel R, Neumann T, Herzog W, Katus H, Muller-Tasch T, Zugck C, Dungen HD, Regitz-Zagrosek V, Lehmkuhl E, Stork S, Siebert U, Wasem J, Neumann A, Gohler A, Anker SD, Kohler F, Mockel M, Osterziel KJ, Dietz R, Rauchhaus M. A network against failing hearts--introducing the German "Competence Network Heart Failure". Int J Cardiol 2010;145(1):135-8.

ABSTRACT

91.

Konig A, Bleie O, Dudek D, Marso S, Rogers JH, Dave R, Tanaka K, Siebert U, Wijns W, Klauss V. Coronary plaque dimensions and composition by intravascular ultrasound radio frequency lesion segment analysis in stable and unstable angina patients. Coron Artery Dis 2009;20(5):309-16.

ABSTRACT

90.

Schwarzer R, Siebert U. Methods, procedures, and contextual characteristics of health technology assessment and health policy decision making: Comparison of health technology assessment agencies in Germany, United Kingdom, France, and Sweden. Int J Technol Assess Health Care 2009;25(3):305-14.

ABSTRACT

89.

Zechmeister I, Blasio BF, Garnett G, Neilson AR, Siebert U. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine 2009;27(37):5133-41.

ABSTRACT

88.

Hellmann-Schoierer J, Bose-O'Reilly S. [Preventive assistants in paediatric outpatient clinics.] Gesundheitswesen 2009;71(06):329-31.

ABSTRACT

87.

Geisler BP, Levin-Scherz JK. Additional factors that could improve cost-effectiveness of pharmacogenetic-guided dosing in warfarin therapy. Ann Intern Med 2009;151(1):71; author reply 71.

ABSTRACT

86.

Geisler BP, van Dam R, Gazelle GS, Goehler A. Risk of bias in meta-analysis on erythropoietin-stimulating agents in heart failure. Heart 2009;95(15):1278-9; author reply 1279.

ABSTRACT

85.

Siebert U, Sroczynski G, Aidelsburger P, Rossol S, Wasem J, Manns MP, McHutchison JG, Wong JB, German Hepatitis C Model (GEHMO) Group, International Hepatitis Interventional Therapy (IHIT) Group. Clinical effectiveness and cost-effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: A decision analysis on new German guidelines. Pharmacoeconomics 2009;27(4):341-54.

ABSTRACT

84.

Schnell-Inderst P, Schwarzer R, Göhler A, Grandi N, Grabein K, Stollenwerk B, Klauss V, Wasem J, Siebert U. Stellenwert des hochsensitiven C-reaktiven Proteins (hs-CRP) als Marker für Herzinfarktgefährdung. Ein Health Technology Assessment im Auftrag des Deutschen Institutes für Medizinische Dokumentation und Information (DIMDI), Berichtsnummer 216, Schriftenreihe Health Technology Assessment Bd. 81, Köln: DIMDI, 2009, pp.1-318.

83.

Schnell-Inderst P, Schwarzer R, Göhler A, Grandi N, Grabein K, Stollenwerk B, Klauß V, Wasem J, U. S. Endbericht zum Stellenwert des hochsensitiven C-reaktiven Proteins (hs-CRP) als Marker für Herzinfarktgefährdung. GMS Health Technol Assess 2009;5(Doc06).

82.

Neumann A, Jahn R, Diehm C, Driller E, Hessel F, Lux G, Ommen O, Pfaff H, Siebert U, Wasem J, and on behalf of the Patient Care Evaluation-Peripheral Arterial Disease (PACE-PAD) Study Investigators. Presentation and medical management of peripheral arterial disease in general practice: rationale, aims, design and baseline results of the PACE-PAD Study. J Public Health 2009;17(2):127-35.

81.

Maringer B, Zietemann V, Ratzinger G, Siebert U. [Effectiveness of omega-3-fatty-acids in psoriasis. A systematic review]. Aktuel Ernahrungsmed 2009;34(4):195-200.

80.

Göhler A, Geisler BP, Manne JM, Kosiborod M, Zhang Z, Weintraub WS, Spertus JA, Gazelle GS, Siebert U, Cohen DJ. Utility Estimates for Decision - Analytic Modeling in chronic heart failure - health states based on New York Heart Association classes and number of rehospitalizations. Value in Health 2009;12(1):185-7.

ABSTRACT

79.

Geisler BP, Siebert U, Gazelle GS, Cohen DJ, Göhler A. Deterministic sensitivity analysis for First-Order Monte Carlo Simulations: A technical note. Value in Health 2009;12(1):96-7.

ABSTRACT

78.

Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009;9(1):34.

ABSTRACT

77.

Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Muhlberger N, Wright D, Zeuzem S, Siebert U. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. Eur J Public Health 2009;19(3):245-53.

ABSTRACT

76.

Stollenwerk B, Gerber A, Lauterbach KW, Siebert U. The German Coronary Artery Disease Risk Screening Model: Development, validation and application of a decision-analytic model for coronary artery disease prevention with statins. Med Decis Making 2009;29:619-33.

ABSTRACT

75.

Siebert U, Conrads-Frank A, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Mühlberger N. DALYs in chronic hepatitis C - a pan-European perspective In: Preedy VR, Watson RR, eds. Handbook of Disease Burdens and Quality of Life Measures. New York: Springer, 2009;1323-1334.

 

2008

74.

Gohler A, Conrads-Frank A, Worrell SS, Geisler BP, Halpern EF, Dietz R, Anker SD, Gazelle GS, Siebert U. Decision-analytic evaluation of the clinical effectiveness and cost-effectiveness of management programmes in chronic heart failure. Eur J Heart Fail 2008;10(10):1026-32.

ABSTRACT

73.

Alimonti A, Bose-O'Reilly S, Moshammer H, van den Hazel PJ. Preface: Children's health and environment. Int J Environment and Health 2008;2(3/4):273-5.

72.

Boese-O'Reilly S, Drasch G, Lettmeier B, Roider G, Siebert U. Reply to the letter to the editor by J.G. Dorea "Health hazard for infants: Breast-milk mercury or non-breastfeeding? A dilemma for mothers exposed to mercury vapours". Int J Hyg Environ Health 2008;212(2):235-7.

71.

Institute for Quality and Efficiency in Health Care (IQWiG). Methods for assessment of the relation of benefits to costs in the German Statutory Health Care System. V. 1.0. (Members of the IQWiG International Expert Panel: Attella V, Caro J, Pouvourville G, Henry D, McGregor M, McGuire A, Nord E, Siebert U). Cologne: IQWiG, 2008;68.

Full Text    

70.

Lob-Corzilius T, Wermuth I, Hellmann J, Petersen E, Böse-O’Reilly S. Präventionsassistentin in der Kinder- und Jugendmedizin. Eine umweltmedizinische Weiterqualifikation für medizinische Assistenzberufe. Umweltmed Forsch Prax 2008;13(6):373-8.

69.

Stock S, Stollenwerk B, Klever-Deichert G, Redaelli M, Buscher G, Graf C, Mohlendick K, Mai J, Gerber A, Lungen M, Lauterbach KW. Preliminary analysis of short-term financial implications of a prevention bonus program: first results from the German Statutory Health Insurance. Int J Public Health 2008;53(2):78-86.

ABSTRACT

68.

Siebert U, Bornschein B, Schnell-Inderst P, Rieber J, Pijls N, Wasem J, Klauss V. [Measurement of fractional flow reserve to guide the decision on percutaneous coronary interventions. [German]. Health Technology Assessment Vol. 69 (Series of the German Institute for Medical Documentation and Information commissioned by the Federal Ministry of Health). Health Technology Assessment  Vol. 69. Cologne: DIMDI, 2008.

67.

Ramoner R, Rahm A, Gander H, Stollenwerk B, Falkensammer C, Leonhartsberger N, Thurnher M. Serum antibodies against Saccharomyces cerevisiae: a new prognostic indicator in metastatic renal-cell carcinoma. Cancer Immunol Immunother 2008;57(8):1207-14.

ABSTRACT

66.

Miksad RA, Zietemann V, Gothe R, Schwarzer R, Conrads-Frank A, Schnell-Inderst P, Stollenwerk B, Siebert U. Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Technol Assess Health Care 2008;24(4):371-83.

ABSTRACT

65.

Graf von der Schulenburg JM, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, Mittendorf T, Rebscher H, Schoeffski O, Vauth C, Volmer T, Wahler S, Wasem J, Weber C. German recommendations on health economic evaluation: Third and updated version of the Hanover Consensus. Value Health 2008;11(4):539-44.

ABSTRACT

64.

Gohler A, Geisler BP, Manne JM, Kosiborod M, Zhang Z, Weintraub WS, Spertus JA, Gazelle GS, Siebert U, Cohen DJ. Utility estimates for decision-analytic modeling in chronic heart failure-health states based on New York Heart Association Classes and number of rehospitalizations. Value Health 2008;12(1):185-7.

ABSTRACT

63.

Boese-O'Reilly S. Das geplante Praeventionsgesetz aus paediatrischer Sicht. Verhältnisse und Verhalten aendern. Weiterbildung 2008;3:8-11.

62.

Boese-O'Reilly S, Hellmann J. . Primaere Praevention und Gesundheitsfoerderung - das geplante Praeventionsgesetz aus paediatrischer Sicht. Weiterbildung 2008;3.

61.

Boese-O'Reilly S, Lettmeier B, Cao TL, Siebert U, Tesha AL, Pronczuk J, et al. Health and environmental training in mercury-contaminated areas. Int J Environment and Health 2008;1(4):621-37.

60.

Boese-O'Reilly S, Lettmeier B, Gothe RM, Beinhoff C, Siebert U, Drasch G. Mercury as a serious health hazard for children in gold mining areas. Environ Res 2008;107(1):89-97.

ABSTRACT

59.

Hellmann J, Boese-O'Reilly S. Prävention und Gesundheitsförderung - mehr als nur Verhütung von Krankheit. Weiterbildung 2008(3):40-43.

58.

Hellmann J, Lob-Corzilius T, Boese-O'Reilly S, Petersen E. Vorbildprojekt zur Vorbeugung - Fünf Jahre Curriculum Prävention im Kindes- und Jugendalter. Weiterbildung 2008(3):16-19.

57.

Drummond M, Schwartz JS, Jönsson B, Luce B, Neumann P, Siebert U, Sullivan S. Response from the authors of "Key principles for the improved conduct of health technology assessments for resource allocation decisions". Int J Technol Assess Health Care 2008;24(3):367-8.

56.

Drummond MF, Schwartz JS, Jönsson B, Luce BR, Neumann PJ, Siebert U, Sullivan SD. Key principles for the improved conduct of health technology assessments for resource allocation decisions.Int J Technol Assess Health Care 2008;24(3):244-58.

ABSTRACT

55.

Ammenwerth E, Schnell-Inderst P, Machan C, Siebert U. The effect of electronic prescribing on medication errors and adverse drug events: A systematic review. J Am Med Inform Assoc 2008;15(5):585-600.

ABSTRACT

54.

Mühlberger N, Sroczynski G, Esteban E, Mittendorf T, Miksad RA, Siebert U. Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: A systematic review commissioned by the German Federal Ministry of Health. International Journal of Technology Assessment in Health Care 2008;24(2):184-92.

ABSTRACT

53.

Lettmeier B; Mühlberger N, Schwarzer E, Sroczynski G, Wright D, Zeuzem S, Siebert U. Market uptake of new antiviral drugs for the treatment of hepatitis C. Journal of Hepatology 2008;49(4):528-36.

ABSTRACT

52.

Boese-O'Reilly S, Wermuth I, Hellmann J, Siebert U, Lob-Corzilius T. [Promotion of breast feeding in paediatric outpatient settings]. [German] Gesundheitswesen 2008;70(Suppl 1):S34-36.

51.

König A, Kilian E, Sohn HY, Rieber J, Schiele TM, Siebert U, Gothe RM, Reichart B, Klauss V. Assessment and characterization of time-related differences in plaque composition by intravascular ultrasound-derived radiofrequency analysis in heart transplant recipients. Journal of Heart & Lung Transplantation 2008;27(3):302-9.

ABSTRACT

50.

Stempfle HU, Alt A, Stief J, Siebert U. The Munich score: a clinical index to predict survival in ambulatory patients with chronic heart failure in the era of new medical therapies. Journal of Heart & Lung Transplantation 2008;27(2):222-8.

ABSTRACT

49.

Siebert U, Bornschein B, Schnell-Inderst P, Rieber J, Pijls N, Wasem J, Klauss V. [Measurement of fractional flow reserve to guide decisions for percutaneous coronary intervention] (German; Original Title: Messung der fraktionierten Flussreserve zur Indikationsstellung der perkutanen Koronarintervention). GMS Health Technol Assess 2008;4(Doc07):1-12.

48.

Siebert U. [Using decision-analytic modelling to transfer international evidence from health technology assessment to the context of the German health care system. A HTA methods report. Series of the German Institute for Medical Documentation and Information commissioned by the Federal Ministry of Health and Social Security] (German; Original Title:Entscheidungsanalytische Modelle zur Sicherung der Übertragbarkeit internationaler Evidenz von HTA auf den Kontext des deutschen Gesundheitssystems). GMS Health Technol Assess 2005;1(Doc03):1-6.

47.

Boese-O'Reilly S, Lettmeier B, Roider G, Siebert U, Drasch G. Mercury in breast milk - A health hazard for infants in gold mining areas? Int J Hyg Environ Health 2008; 211(5-6):615-23.

ABSTRACT

46.

Siebert U, Zietemann V, Sroczynski G. Pharmacogenomics bias - systematic distortion of study results by genetic heterogeneity. [German; original title: Pharmacogenomics-Bias - Systematische Verzerrungen in Studienergebnissen durch genetische Heterogenität]. Health Technology Assessment Vol. 63. (Series of the German Institute for Medical Documentation and Information commissioned by the Federal Ministry of Health). 67 pages. Cologne: DIMDI, 2008.

45.

Stephanie AK, Stock MD, Stollenwerk B, Redaelli M, Civello D, Lauterbach KW. Sex differences in treatment patterns of six chronic diseases: An analysis from the German Statutory Health Insurance. Journal of Women's Health 2008:17:3;Doi: 10.1089/jwh.2007.0422.

44.

Janne d'Othée B, Siebert U, Cury R, Jadvar H, Dunn EJ, Hoffmann U. A systematic review on diagnostic accuracy of CT-based detection of significant coronary artery disease. Eur J Radiol. 2008;65(3):449-61.

ABSTRACT

43.

Lüngen M. Stollenwerk B. Messner P. Lauterbach KW. Gerber A. Waitingtimes for elective treatments according to insurance status: A randomized empirical study in Germany. International Journal for Equity in Health 2008:7:1; doi:10.1186/1475-9276-7-1. 

ABSTRACT

 

2007

42.

Vauth C, Haverkamp A, Mittendorf T, Siebert U, Schulenburg JM, Krauth C. Das Kompetenznetz Hepatitis - Methodische Ansätze und erste Ergebnisse der gesundheitsökonomischen Begleitforschung. Gesundheitsökonomie & Qualitätsmanagement 2007;12(4):203-206.

41.

von der Schulenburg J, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, Mitten-Lewis S, Rebscher H, Schoffski O, Vauth C, Vollmer T, Wahler S, Wasem J, Weber CC, all members of the Hanover Consensus Panel. [German recommendations on health economic evaluation - third and updated version of the Hanover Consensus]. Gesundheitsokonomie und Qualitatsmanagement 2007;12:285-290.

40.

Dodel R, Peter H, Spottke A, Althaus A, Siebert U, Walbert T, Kesper K, Becker HF, Mayer G. Health-related quality of life in patients with narcolepsy. Sleep Medicine 2007:8(7-8):733-41.

ABSTRACT

39.

Meissner OA, Schmedt CG, Hunger K, Hetterich H, Sroka R, Rieber J, Babaryka G, Steckmeier BM, Reiser M, Siebert U, Mueller-Lisse U. Endovascular optical coherence tomography ex vivo: venous wall anatomy and tissue alterations after endovenous therapy. Eur Radiol 2007;17(9):2384-93.

ABSTRACT

38.

Schneider A, Schwarz TF, Hammerschmidt T, Rash RM, Siebert U.[Treatment patterns and costs of unclear and abnormal cervicalconditions in Germany]. [German] Geburtshilfe und Frauenheilkunde 2007;67(8):859-865. 

37.

Schneider A, Hammerschmidt T, Schwarz TF, Rogoza RM, Ferko N,Siebert U. [Long-term public health impact of vaccination againstcervical cancer in Germany]. [German] Geburtshilfe und Frauenheilkunde 2007;67(8):850-858. 

36.

Schneider A, Schwarz TF, Hammerschmidt T, Siebert U. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany]. [German] Medizinische Klinik 2007; 102(7):515-23.

ABSTRACT

35.

Fearon WF, Tonino PA, De Bruyne B, Siebert U, Pijls NHJ, for the FAME Study Investigators. Rationale and design of the fractional flow reserve versus angiography for multivessel evaluation (FAME) study. American Heart Journal 2007;154(4):632-6. Correction: Am Heart J 2007;154(6):1243.

ABSTRACT

34.

König A, Leibig M, Rieber J, Schiele TM, Theisen K, Siebert U, Gothe RM, Klauss V. Randomized comparison of dexamethasone-eluting stents with bare metal stent implantation in patients with acute coronary syndrome: serial angiographic and sonographic analysis. American Heart Journal 2007;153(6):979.e1-8. 

ABSTRACT

33.

Müller T, Koppikar S, Taylor RM, Carragher F, Schlenck B, Heinz-Erian P, Kronenberg F, Ferenci P, Tanner S, Siebert U, Staudinger R, Mieli-Vergani G, Dhawan A. Re-evaluation of the penicillamine challenge test in the diagnosis of Wilson's disease in children. J Hepatol 2007; 47(2):270-6. 

32.

Dodel R, Peter H, Spottke A, Althaus A, Siebert U, Walbert T, Kesper K, Becker HF, Mayer G. Health-related quality of life in patients with narcolepsy. Sleep Med 2007;8(7-8):733-41. 

ABSTRACT

31.

Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP Titel: Rate of clinical progression in Parkinson's disease. A prospective study. Mov Disord 2007; 22(7):938-45. 

ABSTRACT

30.

Zietemann V, Zietemann P, Weitkunat R, Kwetkat A. [Relation between certain diseases and frequency of depression in geriatric patients]. Nervenarzt 2007;78(6):657-64.

ABSTRACT

29.

Siebert U. Cost-Effectiveness. In: King and Yeung (eds.). Interventional Cardiology. McGraw-Hill, New York: 2007, 767-82.

28.

Mühlberger N, Sroczynski G, Lettmeier B, Schwarzer R, Esteban E, Conrads-Frank A, Zeuzem S, Siebert U. Results of the PanEuropean Hepatitis C Project. Presentation at the China HCV Management Forum Beijing, 16 November 2007.

Full Text

27.

Boese-O'Reilly S. Continuous medical education (CME): do we need CME for paediatric environmental medicine in Europe? Int J Hyg Environ Health 2007;210(5):531-4.

ABSTRACT

26.

Böse-O'Reilly S, Heudorf U, Lob-Corzilius T, von Muhlendahl KE, Otto M, Schmidt S. Children's environment in Central Europe: threats and chances. Int J Hyg Environ Health 2007;210(5):503-7.

ABSTRACT

25.

Drasch G, Boese-O'Reilly S, Illig S. Increase of renal excretion of organo-mercury compounds like methlymercury by DMPS (2,3-Dimercapto-1-propanesulfonic acid, Dimaval). Clin Toxicol (Phila) 2007;45(3):266-9.

ABSTRACT

24.

Boese-O'Reilly S, Glück-Kretschmer C, Reese I, Gießler-Fichtner O. Neurodermitisschulung in der kinder- und jugendärztlichen Praxis. Pädiatrische Allergologie 2007;10(Sonderheft Asthma und Neurodermitisschulung):45-46.

 

2006

23.

Siebert U, Januzzi JL Jr, Beinfeld MT, Cameron R, Gazelle GS. Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. American Journal of Cardiology, 2006, 98 (6): 800-5.

ABSTRACT

22.

Göhler A, Januzzi JL, Worrell SS, Osterziel KJ, Gazelle GS, Dietz R, Siebert U. A Systematic meta-analysis of the efficacy and heterogeneity of disease management programs in congestive heart failure. J Cardiac Failure 2006, 12 (7): 554-67.

ABSTRACT

21.

Basner M, Siebert U. Markov processes for prediction of aircraft-noise effects on sleep [Original title: Markov-Prozesse zur Vorhersage fluglaermbedingter Schlafstoerungen]. Somnologie 2006;10:176-191. 

20.

Siebert U. [Decision Analysis]: In: Schlipköter U, Wildner M (eds.): [Manual of Infectious Diseases Epidemiology] Hans Huber, Bern: 2006; 87-95. 

19.

Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A, Stein K. The costeffectiveness of testing for hepatitis C in former injecting drug users. Health Technol Assess 2006;10(32):1-93.

ABSTRACT

18.

Boese-O'Reilly S. Neue umweltmedizinische Weiterbildung für Kinder- und Jugendärzte. Pädiatrische Allergologie 2006;9:38-39.

17.

Boese-O'Reilly S, Lob-Corzilius T. Praktisches Vorgehen bei Verdacht auf eine umweltbedingte Erkrankung bei Kindern und Jugendlichen. Pädiatrische Allergologie 2006;9:28-32.

16.

Boese-O'Reilly S, Gerber A, Feyer I, Lauterbach KW. Umweltbedingte Kosten in der Pädiatrie. In: Gerber A, Lauterbach KW, editors. Gesundheitsökonomie und Pädiatrie. Stuttgart: Schattauer; 2006. p. 91-103.

15.

Thompson Coon J, Castelnuovo E, Pitt M, Cramp M, Siebert U, Stein K. Case finding for hepatitis C in primary care: a cost utility analysis. Fam Pract 2006;23(4):393-406.

ABSTRACT

14.

Basner M, Siebert U. Markov processes for prediction of aircraft-noise effects on sleep [Original title: Markov-Prozesse zur Vorhersage fluglaermbedingter Schlafstoerungen]. Somnologie 2006;10:176-191.

13.

Siebert U. Entscheidungsanalysen in HTA. Ziele, Stärken, Limitationen. HTA-Newsletter ITA/Österreichische Akademie der Wissenschaften 2006 (45): 1-2.

12.

Rohde V, Grabein K, Hessel F, Siebert U, Wasem J. Orchiektomie versus medikamentöse Therapie mit LH-RH-Analoga zur Behandlung des fortgeschrittenen Prostatakarzinoms. Health Technology Assessment Vol. 140. Serie des Deutschen Instituts für Medizinische Dokumentation und Information, im Auftrag des Bundesministeriums für Gesundheit. Köln: DIMDI, 2006.

11.

Sroczynski G, Rafetseder O. Jonas S., Siebert U. Antivirale Kombinationstherapie bei Patienten mit chronischer Hepatitis C in Österreich. Gesundheitsökonomische Evaluation der Kombinationstherapie mit Interferon/Peginterferon und Ribavirin. ITA-Projektbericht Nr. b29 . (48 pages. Vienna: Institut für Technologiefolgenabschätzung, Österreichische Akademie der Wissenschaften, 2006.

10.

Hoffmann U, Pena AJ, Cury RC, Abbara S, Ferencik M, Moselewski F, Siebert U, Brady TJ, Nagurney JT. Cardiac CT in emergency department patients with acute chest pain. Radiographics 2006;26(4):963-978; discussion 979-80.

ABSTRACT

09.

Cury RC, Cattani CA, Gabure LA, Racy DJ, de Gois JM, Siebert U, Lima SS, Brady TJ. Diagnostic performance of stress perfusion and delayed-enhancement MR imaging in patients with coronary artery disease. Radiology 2006;240(1):39-45.

ABSTRACT

08.

Rieber J. Huber A, Erhard I, Mueller S, Schweyer M, Koenig A, Schiele TM, Theisen K, Siebert U, Schoenberg SO, Reiser M, Klauss V. Cardiac magnetic resonance perfusion imaging for the functional assessment of coronary artery disease: A comparison with coronary angiography and fractional flow reserve. European Heart Journal 2006;27(12):1456-71.

ABSTRACT

07.

Siebert U, Sroczynski G, Hillemanns P, Engel J, Stabenow R, Stegmaier C, Voigt K, Gibis B, Hölzel D, Goldie SJ. The German Cervical Cancer Screening Model: Development and validation of a decisionanalytic model for cervical cancer screening in Germany. Eur J Pub Health 2006;16(2):185-92.

ABSTRACT

06.

Hoffmann U. Siebert U. Bull-Stewart A. Achenbach S. Ferencik M. Moselewski F. Brady TJ. Massaro JM. O'Donnell CJ. Evidence for lower variability of coronary artery calcium mineral mass measurements by multi-detector computed tomography in a community-based cohort--consequences for progression studies. Eur J Radiol 2006;57(3):396-402.

ABSTRACT

05.

Meissner OA. Rieber J. Babaryka G. Oswald M. Reim S. Siebert U. Redel T. Reiser M. Mueller-Lisse U. Intravascular optical coherence tomography: comparison with histopathology in atherosclerotic peripheral artery specimens. J Vasc Interv Radiol 2006;17(2):343-9.

ABSTRACT

04.

Meissner OA. Rieber J. Babaryka G. Oswald M. Reim S. Siebert U. Redel T. Eibel R. Mueller-Lisse U. Reiser M. Mueller-Lisse UG. [Intravascular optical coherence tomography: differentiation of atherosclerotic plaques and quantification of vessel dimensions in crural arterial specimens]. [German] Rofo 2006;178(2):214-20.

ABSTRACT

03.

Wasem J. Sroczynski G. Aidelsburger P. Buchberger B. Hessel F. Conrads-Frank A. Peters-Blöchinger A. Kurth BM. Wong JB. Rossol S. Siebert U. [Health economics of chronic infectious diseases: the example of hepatitis C]. [German] Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2006;49(1):57-63.

ABSTRACT

02.

Haacke C, Althaus A, Spottke A, Siebert U, Back T, Dodel R. Long-term outcome after stroke: evaluating health-related quality of life using utility measurements. Stroke 2006;37(1):193-8.

ABSTRACT

01.

Baggish AL, Siebert U, Lainchbury JG, Cameron R, Anwaruddin S, Chen A, Krauser DG, Tung R, Brown DF, Richards AM, Januzzi JL Jr. A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score. Am Heart J 2006;151(1):48-54.

ABSTRACT